AD57 (hydrochloride) – 5 mg

Brand:
Cayman
CAS:
2320261-72-9
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Complex diseases, like cancer, may best be countered by compounds that affect multiple targets. AD57 is a polypharmacological cancer therapeutic, in that it is designed to modulate multiple targets related to cancer.{21665} In Drosophila, it potently inhibits the receptor tyrosine kinase RET (IC50 = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 μM.{21665} Most notably, AD57 interferes with kinases downstream of RET, including Src, Raf, and S6K, providing further efficacy in preventing signaling leading to invasion, proliferation, and metabolism relevant to cancer.{21665}  

 

SKU: - Category:

Description

A polypharmacological cancer therapeutic; potently inhibits RET (IC50 = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 μM in Drosophila; interferes with kinases downstream of RET, including Src, Raf, and S6K


Formal name: N-[4-[4-amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N’-[3-(trifluoromethyl)phenyl]-urea, monohydrochloride

Synonyms: 

Molecular weight: 491.9

CAS: 2320261-72-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling